

CHARITÉ/BIH-PARTNER WANTED!
 More information [here](#)

Short profile

Fize Medical

Medical field	Intensive care, Covid-19 specialty departments, Surgery, Cardiology, Primary Care, Urology, Other
Product	NephroLog, Medical Device
Growth stage	Positioning for Scale
Founders	Dror Zerem (CEO), Noam Levine (Founder, CTO)

Description of product:

A platform for point of care urine measuring and analysis. The device is non-invasive and connected through a disposable kit to a Foley catheter. The device allows remote monitoring and caregiver-patient distancing.

Project goal:

We are currently focusing on refining the user experience and preparing the first product for mass production.

Project type:

Our project consists of 4 main parts:

1. beta testing for almost finalized first device, which measures the urine output in real time, This part requires few weeks of onsite usability tests and a small-scale clinical trial under local IRB committee approval to demonstrate accuracy and utility. The output will lead to product refining and fast commercialization, hoping to bring value during the COVID-19 crisis.
2. Confirmation of the NephroLog system to predict shock and AKI, as we observed in our clinical trial. This trial would be designed to determine more specific thresholds for clinical intervention. We expect to publish an article based on this trial to support our technology acknowledgment in the clinical community and include it into the relevant societies' clinical guidelines.
3. Co-development of online urine analysis and its integration into the predictive algorithm. Fize will provide the technological platform, while the hospitals will provide some clinical direction on the most valuable information, we could provide in real-time. This will result in enhanced hardware features, advancement of the software and the predictive algorithm.
4. Business and operations round table that will help us bring our commercialization plan to fruition. We anticipate that this will yield quicker and more robust commercial results, helping to penetrate the most important markets.

International Health-Tech
 Pilot Program with
**World-Leading
Hospitals**